O Abdel-Rahman1,2. 1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. omar.abdelrhman@med.asu.edu.eg. 2. Department of Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, AB, Canada. omar.abdelrhman@med.asu.edu.eg.
Abstract
BACKGROUND: The current analysis aims to evaluate the impact of statin co-treatment on the survival of patients with metastatic pancreatic cancer. METHODS: This is a pooled analysis of de-identified patient data from two clinical trials (NCT01124786; NCT00844649). Overall and progression-free survival according to patient subsets (patients who received or who did not receive statins) were assessed through Kaplan-Meier analysis and log-rank test. Univariate and multivariate Cox regression analysis was performed to evaluate different factors potentially affecting overall and progression-free survival. Propensity score matching was performed to address heterogeneity in baseline characteristics of different subgroups of patients. RESULTS: A total of 797 patients were assessed in the current study; of which 156 patients received statins and 641 did not receive statins. Using Kaplan-Meier survival estimates, patients who received statins seem to have better overall and progression-free survival compared to patients who did not (P = 0.008; P < 0.001, respectively). In multivariate analysis for factors affecting overall survival, the following factors were associated with worse overall survival: worse performance status (P < 0.001), no statin use (P = 0.044) and multiple sites of metastatic disease (P = 0.023); likewise in multivariate analysis for factors affecting progression-free survival, the following factors were associated with worse progression-free survival: worse performance status (P < 0.001), gemcitabine elaidate chemotherapy (P = 0.015) and no statin use (P = 0.048). Following propensity score matching and using Kaplan-Meier estimates, statin use was also associated with better overall and progression-free survival (P = 0.005; P = 0.040, respectively). CONCLUSION: Statin use seems to be associated with better overall survival among patients with metastatic pancreatic cancer treated with first-line chemotherapy. Prospective studies designed specifically to assess this potential effect of statins are needed.
BACKGROUND: The current analysis aims to evaluate the impact of statin co-treatment on the survival of patients with metastatic pancreatic cancer. METHODS: This is a pooled analysis of de-identified patient data from two clinical trials (NCT01124786; NCT00844649). Overall and progression-free survival according to patient subsets (patients who received or who did not receive statins) were assessed through Kaplan-Meier analysis and log-rank test. Univariate and multivariate Cox regression analysis was performed to evaluate different factors potentially affecting overall and progression-free survival. Propensity score matching was performed to address heterogeneity in baseline characteristics of different subgroups of patients. RESULTS: A total of 797 patients were assessed in the current study; of which 156 patients received statins and 641 did not receive statins. Using Kaplan-Meier survival estimates, patients who received statins seem to have better overall and progression-free survival compared to patients who did not (P = 0.008; P < 0.001, respectively). In multivariate analysis for factors affecting overall survival, the following factors were associated with worse overall survival: worse performance status (P < 0.001), no statin use (P = 0.044) and multiple sites of metastatic disease (P = 0.023); likewise in multivariate analysis for factors affecting progression-free survival, the following factors were associated with worse progression-free survival: worse performance status (P < 0.001), gemcitabine elaidate chemotherapy (P = 0.015) and no statin use (P = 0.048). Following propensity score matching and using Kaplan-Meier estimates, statin use was also associated with better overall and progression-free survival (P = 0.005; P = 0.040, respectively). CONCLUSION: Statin use seems to be associated with better overall survival among patients with metastatic pancreatic cancer treated with first-line chemotherapy. Prospective studies designed specifically to assess this potential effect of statins are needed.
Authors: M M Vickers; E D Powell; T R Asmis; D J Jonker; J F Hilton; C J O'Callaghan; D Tu; W Parulekar; M J Moore Journal: Eur J Cancer Date: 2011-11-24 Impact factor: 9.162
Authors: Bechien U Wu; Jonathan Chang; Christie Y Jeon; Stephen J Pandol; Brian Huang; Eunis W Ngor; Andrew L Difronzo; Robert M Cooper Journal: Am J Gastroenterol Date: 2015-07-21 Impact factor: 10.864
Authors: Margaret A Tempero; Mokenge P Malafa; Stephen W Behrman; Al B Benson; Ephraim S Casper; E Gabriela Chiorean; Vincent Chung; Steven J Cohen; Brian Czito; Anitra Engebretson; Mary Feng; William G Hawkins; Joseph Herman; John P Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Andrew M Lowy; Wen Wee Ma; Nipun B Merchant; Sean J Mulvihill; Peter Muscarella; Eric K Nakakura; Jorge Obando; Martha B Pitman; Sushanth Reddy; Aaron R Sasson; Sarah P Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer L Burns; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-08 Impact factor: 11.908
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Christie Y Jeon; Stephen J Pandol; Bechien Wu; Galen Cook-Wiens; Roberta A Gottlieb; C Noel Bairey Merz; Noel Bairey Merz; Marc T Goodman Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240
Authors: Madeleine Dorsch; Manuela Kowalczyk; Mélanie Planque; Geronimo Heilmann; Sebastian Urban; Philip Dujardin; Jan Forster; Kristina Ueffing; Silke Nothdurft; Sebastian Oeck; Annika Paul; Sven T Liffers; Farnusch Kaschani; Markus Kaiser; Alexander Schramm; Jens T Siveke; Monte M Winslow; Sarah-Maria Fendt; Perihan Nalbant; Barbara M Grüner Journal: Cell Rep Date: 2021-11-23 Impact factor: 9.423
Authors: Xin Hong; Whijae Roh; Ryan J Sullivan; Keith H K Wong; Ben S Wittner; Hongshan Guo; Taronish D Dubash; Moshe Sade-Feldman; Benjamin Wesley; Elad Horwitz; Genevieve M Boland; Dieuwke L Marvin; Todd Bonesteel; Chenyue Lu; François Aguet; Risa Burr; Samuel S Freeman; Laxmi Parida; Katherine Calhoun; Michelle K Jewett; Linda T Nieman; Nir Hacohen; Anders M Näär; David T Ting; Mehmet Toner; Shannon L Stott; Gad Getz; Shyamala Maheswaran; Daniel A Haber Journal: Cancer Discov Date: 2020-11-17 Impact factor: 39.397